Regeneron’s Eylea franchise remains resilient despite biosimilar competition. Read what makes REGN stock a Strong Buy despite ...

Eylea does not have any known drug interactions. However, it’s still important to talk with your doctor about all medications, supplements, and vitamins you use before starting treatment with Eylea.

Emergen Research Logo The development of anti-VEGF therapies, which inhibit the growth of abnormal blood vessels in the retina, reduces the ...

As biotech investors know, companies in the industry can sometimes earn significant returns in relatively short periods, like ...

An add-on agent designed to boost drugs that treat age-related macular degeneration failed to show any benefit in two phase 3 ...

Oppenheimer lowered the firm’s price target on Regeneron (REGN) to $925 from $950 and keeps an Outperform rating on the shares. The firm is ...

William Blair initiated coverage of Kalaris Therapeutics (KLRS) with an Outperform rating and $21 fair value estimate. Kalaris is a clinical-stage ...

The global Age-Related Macular Degeneration (AMD) Market is poised for significant expansion over the next decade, with its value expected to grow from US$ 11.31 billion in 2023 to US$ 19.72 billion ...

Apple's growth these days is a bit modest, as revenue for the last three months of 2024 was up just 4%, but it still has ...

Regeneron Pharmaceuticals (NasdaqGS:REGN) saw its share price decline by 10% over the past week. The recent approval of Dupixent for COPD in Japan was expected to bolster investor confidence, yet the ...

With the FDA appearing to be undergoing major disruption under new leadership, BofA analyst Tim Anderson says one way to assess the risk from ...